Journal articles
Hall BM; Hodgkinson SJ; Quin JW, 1999, 'Corticosteroids in Autoimmunity', Australian Prescriber, pp. 15 - 18
Hall BM; Hodgkinson SJ; Quin JW, 1998, 'Corticosteroids in autoimmune diseases.', Australian Prescriber, pp. 9 - 11
Hu P; Pollard J; Hunt N; Taylor J; Hodgkinson S; Tran G; ChanLing T, 1997, 'Pathogenesis of optic neuritis in experimental allergic encephalomyelitis (EAE)', BRAIN PATHOLOGY, 7, pp. 1363 - 1363, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997XQ52700525&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Van Oosten BW; Lai M; Hodgkinson S; Barkhof F; Miller DH; Moseley IF; Thompson AJ; Rudge P; McDougall A; McLeod JG; Adèr HJ; Polman CH, 1997, 'Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR- monitored phase II trial', Neurology, 49, pp. 351 - 357, http://dx.doi.org/10.1212/WNL.49.2.351
Murwani R; Hodgkinson S; Armati P, 1996, 'Tumor necrosis factor α and interleukin-6 mRNA expression in neonatal Lewis rat Schwann cells and a neonatal rat Schwann cell line following interferon γ stimulation', Journal of Neuroimmunology, 71, pp. 65 - 71, http://dx.doi.org/10.1016/S0165-5728(96)00131-2
Miller DH; Albert PS; Barkhof F; Francis G; Frank JA; Hodgkinson S; Lublin FD; Paty DW; Reingold SC; Simon J, 1996, 'Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis', Annals of Neurology, 39, pp. 6 - 16, http://dx.doi.org/10.1002/ana.410390104
Van Oosten BW; Lai M; Barkhof F; Miller DH; Moseley IF; Thompson AJ; Hodgkinson S; Polman CH, 1996, 'A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis', Multiple Sclerosis, 1, pp. 339 - 342, http://dx.doi.org/10.1177/135245859600100611
Barkhof F; Thompson AJ; Hodgkinson S; van Oosten B; Lai M; Polman CH; McLeod J; Rudge P; Moseley IF; Ader H, 1995, 'Double-blind, placebo-controlled, MR monitored exploratory trial of chimeric anti-CD4 antibodies in MS.', Journal of Neuroimmunology, 56-63, pp. 15 - 15, http://dx.doi.org/10.1016/0165-5728(95)98902-n
Lindsey JW; Hodgkinson S; Mehta R; Siegel RC; Mitchell DJ; Lim M; Piercy C; Tram T; Dorfman L; Enzmann D; Steinman L, 1994, 'Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis', Neurology, 44, pp. 413 - 419, http://dx.doi.org/10.1212/wnl.44.3_part_1.413
Lindsey RJW; Hodgkinson S; Mehta R; Mitchell D; Enzmann D; Steinman L, 1994, 'Repeated treatment with chimeric anti‐CD4 antibody in multiple sclerosis', Annals of Neurology, 36, pp. 183 - 189, http://dx.doi.org/10.1002/ana.410360210
Hodgkinson SJ; Westland KW; Pollard JD, 1994, 'Transfer of experimental allergic neuritis by intra neural injection of sensitized lymphocytes', Journal of the Neurological Sciences, 123, pp. 162 - 172, http://dx.doi.org/10.1016/0022-510X(94)90219-4
Bell RB; Lindsey JW; Sobel RA; Hodgkinson S; Steinman L, 1993, 'Diverse T cell receptor Vβ gene usage in the central nervous system in experimental allergic encephalomyelitis', Journal of Immunology, 150, pp. 4085 - 4092
Steinman L; Lindsey JW; Alters S; Hodgkinson S, 1993, 'From treatment of experimental allergic encephalomyelitis to clinical trials in multiple sclerosis.', Immunology series, 59, pp. 253 - 260
Smilek DE; Wraith DC; Hodgkinson S; Dwivedy S; Steinman L; McDevitt HO, 1991, 'A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis', Proceedings of the National Academy of Sciences of the United States of America, 88, pp. 9633 - 9637
Knox SJ; Levy R; Hodgkinson S; Bell R; Brown S; Wood GS; Hoppe R; Abel EA; Steinman L; Berger RG; Gaiser C; Young G; Bindl J; Hanham A; Reichert T, 1991, 'Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides', Blood, 77, pp. 20 - 30
Hodgkinson SJ; Pollard JD; McLeod JG, 1990, 'Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy', Journal of Neurology Neurosurgery and Psychiatry, 53, pp. 327 - 330, http://dx.doi.org/10.1136/jnnp.53.4.327
Sakai K; Zamvil SS; Mitchell DJ; Hodgkinson S; Rothbard JB; Steinman L, 1989, 'Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins', Proceedings of the National Academy of Sciences of the United States of America, 86, pp. 9470 - 9474, http://dx.doi.org/10.1073/pnas.86.23.9470
Conference Papers
Wiendl H; De Stefano N; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Jin H; Jarvinen E; Chudecka A; Gardner L, 2023, 'Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study (S16.006)', in Neurology, Ovid Technologies (Wolters Kluwer Health), http://dx.doi.org/10.1212/wnl.0000000000202961
De Stefano N; Achiron A; Barkhof F; Chan A; Derfuss T; Hodgkinson S; Leocani L; Montalban X; Prat A; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Smyk A; Gardner L, 2023, 'Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study (P6-3.018)', in Neurology, Ovid Technologies (Wolters Kluwer Health), http://dx.doi.org/10.1212/wnl.0000000000202977
Hardy T; Aouad P; Barnett M; Blum S; Broadley S; Carroll W; Crimmins D; Griffiths D; Hodgkinson S; Lechner-Scott J; Lee A; Malhotra R; McCombe P; Parratt J; Plummer C; Walt AVD; Martel K; Walker R, 2023, '2723 Secondary progressive multiple sclerosis patients in Australia treated with siponimod; novel real-world evidence from the MSGo digital support program', in Poster Abstract, BMJ Publishing Group Ltd, presented at ANZAN Annual Scientific Meeting 2023 Abstracts, http://dx.doi.org/10.1136/bmjno-2023-anzan.113
Hardy T; Aouad P; Blum S; Broadley S; Carroll W; Crimmins D; Griffiths D; Hodgkinson S; Lechner-Scott J; Lee A; Malhotra R; Parratt J; Plummer C; Walt AVD; Walker R, 2022, '2258 Novel generation of real-world evidence through MSGo, a digital support program supporting the use of siponimod in secondary progressive multiple sclerosis patients in Australia', in Abstracts, BMJ Publishing Group Ltd, presented at ANZAN Annual Scientific Meeting 2022 Abstracts, http://dx.doi.org/10.1136/bmjno-2022-anzan.64
Vitkova M; Diouf I; Malpas C; Barnett M; Hodgkinson S; Butler E; Slee M; Taylor B; Butzkueven H; Lechner-Scott J; McCombe P; Vucic S; Macdonell R; Shaw C; Kalincik T, 2022, '2327 Latitude, UVR and multiple sclerosis severity', in Abstracts, BMJ Publishing Group Ltd, presented at ANZAN Annual Scientific Meeting 2022 Abstracts, http://dx.doi.org/10.1136/bmjno-2022-anzan.29
Yeh WZ; Widyastuti PA; Walt AVD; Stankovich J; Havrdova EK; Horakova D; Vodehnalova K; Ozakbas S; Eichau S; Duquette P; Kalincik T; Patti F; Boz C; Terzi M; Yamout B; Lechner-Scott J; Sola P; Skibina O; Barnett M; Onofrj M; Sá MJ; McCombe P; Grammond P; Ampapa R; Grand’Maison F; Bergamaschi R; Spitaleri DLA; Pesch VV; Cartechini E; Hodgkinson S; Soysal A; Saiz A; Gresle M; Uher T; Maimone D; Turkoglu R; Hupperts RMM; Amato MP; Granella F; Oreja-Guevara C; Altintas A; Macdonell R; Castillo-Trivino T; Butzkueven H; Alroughani R; Jokubaitis VG; Registry M, 2021, '004 Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis', in Oral abstracts, BMJ Publishing Group Ltd, presented at ANZAN Annual Scientific Meeting 2021 Abstracts, http://dx.doi.org/10.1136/bmjno-2021-anzan.4
Diouf I; Malpas CB; Sharmin S; Skibina O; Buzzard K; Lechner-Scott J; Barnett M; Hodgkinson S; Slee M; Butler E; McCombe P; Walt AVD; Butzkueven H; Vucic S; Macdonell R; Shaw C; Kalincik T, 2021, '006 Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models', in Oral abstracts, BMJ Publishing Group Ltd, presented at ANZAN Annual Scientific Meeting 2021 Abstracts, http://dx.doi.org/10.1136/bmjno-2021-anzan.6
Roos I; Malpas CB; Leray E; Buzzard K; Skibina O; Lechner-Scott J; McCombe P; Slee M; Butler E; Macdonell R; Walt AVD; Hodgkinson S; Barnett M; Vucic S; Vukusic S; Butzkueven H; Kalincik T, 2021, '008 Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis', in Oral abstracts, BMJ Publishing Group Ltd, presented at ANZAN Annual Scientific Meeting 2021 Abstracts, http://dx.doi.org/10.1136/bmjno-2021-anzan.8
Butzkueven H; Spelman T; Kalincik T; Buzzard K; Walt AVD; Lechner-Scott J; Hodgkinson S; Butler E; Macdonell R; Slee M; Group MS; Marcel B, 2021, '010 Real-world experience with ocrelizumab in the MSBase registry – Australian RRMS cohort', in Oral abstracts, BMJ Publishing Group Ltd, presented at ANZAN Annual Scientific Meeting 2021 Abstracts, http://dx.doi.org/10.1136/bmjno-2021-anzan.10
Yeh W; Widyastuti P; Van der Walt A; Stankovich J; Gresle M; Havrdova E; Horakova D; Vodehnalova K; Ozakbas S; Eichau S; Duquette P; Kalincik T; Patti F; Boz C; Terzi M; Yamout B; Lechner-Scott J; Sola P; Skibina O; Barnett M; Onofrj M; Sa MJ; Mccombe P; Grammond P; Ampapa R; Grand'Maison F; Bergamaschi R; Spitaleri D; Van Pesch V; Cartechini E; Hodgkinson S; Soysal A; Saiz A; Uher T; Maimone D; Turkoglu R; Hupperts R; Amato MP; Granella F; Oreja-Guevara C; Altintas A; Macdonell R; Castillo-Trivino T; Butzkueven H; Alroughani R; Jokubaitis V, 2020, 'Pregnancy in a modern day multiple sclerosis cohort: predictors of relapse during pregnancy', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, ELECTR NETWORK, pp. 30 - 31, presented at 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), ELECTR NETWORK, 11 September 2020 - 13 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000596547100057&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Butzkueven H; Spelman T; Hodgkinson S; Kalincik T; Buzzard K; Skibina O; Eichau Madueno S; Izquierdo G; Van der Walt A; Grand-Maison F; Butler E; Prevost J; Mccombe P; Oh J; Macdonell R; Lechner-Scott J; Van Pesch V; Duquette P; Prat A; Girard M; Kermode A; Fabris J, 2020, 'Real-world experience with cladribine tablets in the msbase registry', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, ELECTR NETWORK, pp. 549 - 549, presented at 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), ELECTR NETWORK, 11 September 2020 - 13 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000596547101671&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
De Stefano N; Achiron A; Barkhof F; Chan A; Derfuss T; Hodgkinson S; Leocani L; Montalbant X; Pratt A; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Roy S, 2020, 'A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY- MS Baseline Analysis', in EUROPEAN JOURNAL OF NEUROLOGY, WILEY, ELECTR NETWORK, pp. 685 - 686, presented at 6th Congress of the European-Academy-of-Neurology (EAN), ELECTR NETWORK, 23 May 2020 - 26 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000534616801566&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Malpas CB; Roos I; Sharmin S; Butzkueven H; Kappos L; Patti F; Alroughani R; Horakova D; Havrdova EK; Izquierdo G; Eichau S; Hodgkinson S; Grammond P; Lechner-Scott J; Kalincik T, 2019, 'Disease reactivation following fingolimod cessation', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, SWEDEN, Stockholm, pp. 330 - 331, presented at 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, SWEDEN, Stockholm, 11 September 2019 - 13 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303101223&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Butzkueven H; Spelman T; Patti F; Eichau S; Grand'Maison F; Kalincik T; Hodgkinson S; Skibina O; Butler E, 2019, 'Real-world experience with Cladribine in the MSBase Registry', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, SWEDEN, Stockholm, pp. 326 - 327, presented at 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, SWEDEN, Stockholm, 11 September 2019 - 13 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303101217&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Butzkueven H; Spelman T; Patti F; Ozakbas S; Eichau S; Alroughani R; Terzi M; Boz C; Grand'Maison F; Grammond P; Kalincik T; Van Pesch V; Lechner-Scott J; Barnett M; Kuhle J; Hodgkinson S; Skibina O; Soysal A; Butler E; Slee M; Prevost J; Laureys G; Macdonell R; van Beek J; Craveiro L; Wormser D; Muros-Le Rouzic E, 2019, 'Real-world experience with Ocrelizumab in the MSBase Registry', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, SWEDEN, Stockholm, pp. 539 - 540, presented at 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, SWEDEN, Stockholm, 11 September 2019 - 13 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303102197&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hall BM; Verma ND; Robinson CM; Wang C; Sharland A; Tran G; Wilcox P; Hodgkinson SJ, 2019, 'Recently alloactivated CD4(+)CD8(-)CD25(+)T regulatory cells express CD8alpha and are potent suppressor cells', in JOURNAL OF IMMUNOLOGY, AMER ASSOC IMMUNOLOGISTS, CA, San Diego, presented at 103rd Annual Meeting of the American-Association-of-Immunologists, CA, San Diego, 09 May 2019 - 13 May 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000524982500109&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hodgkinson S; Sharma M, 2019, 'Temporal profile of lymphocytes following treatment with cladribine tablets in patients switching from lymphocyte depleting or sequestering diseased modifying drugs (DMDs)', in NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PA, Philadelphia, presented at 71st Annual Meeting of the American-Academy-of-Neurology (AAN), PA, Philadelphia, 04 May 2019 - 10 May 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000475965903372&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Kalincik T; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Lechner-Scott J; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Solaro C; Grand'Maison F; Hupperts R; Prevost J; Sola P; Ferraro D; Terzi M; Butler E; Slee M; Kermode A; Fabis-Pedrini M; McCombe P; Barnett M; Shaw C; Hodgkinson S; Butzkueven H, 2017, 'Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, FRANCE, Paris, pp. 596 - 597, presented at 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), FRANCE, Paris, 25 October 2017 - 28 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413730203308&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Kalincik T; Spelman T; Jokubaitis V; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Lugaresi A; Grammond P; Alroughani R; Lechner-Scott J; Prevost J; Terzi M; Grand'Maison F; Boz C; Trojano M; Van Wijmeersch B; Pucci E; Granella F; Turkoglu R; Sola P; Ferraro D; McCombe P; Solaro C; Van Pesch V; Ozakbas S; Slee M; Spitaleri D; Sanchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Vucic S; Butzkueven H, 2017, 'Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, FRANCE, Paris, pp. 325 - 327, presented at 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), FRANCE, Paris, 25 October 2017 - 28 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413730202066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Haartsen J; Spelman T; Baker J; Agland S; Lechner-Scott J; Burke T; Vucic S; Rath L; Skibina O; Toubia M; Slee M; Taylor B; Mac Gregor S; Oconnell AM; Barnett M; Baker S; Sharma M; Hodgkinson S; Walters S; Kermode A; Hayes W; Butler E; Sheuy N; Shaw C; Portley R; Hardy T; Tan IL; Butzkueven H, 2017, 'MS FIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, FRANCE, Paris, pp. 403 - 404, presented at 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), FRANCE, Paris, 25 October 2017 - 28 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413730202177&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Spelman T; Schulz M; Arora B; Chung E; Juneja P; Walker R; Verhaeghe S; Butzkueven H; Hodgkinson S; Lechner-Scott J; McCombe P; Slee M; Butler E; Barnett M; Skibina O; Vucic S; Macdonell R; Shuey N; Taylor B; Broadley S, 2017, 'Persistence to fingolimod compared with other disease modifying therapies in the Australian real-world setting using the MS base registry', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, FRANCE, Paris, pp. 631 - 631, presented at 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), FRANCE, Paris, 25 October 2017 - 28 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413730204050&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kapos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H, 2017, 'Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, FRANCE, Paris, pp. 356 - 357, presented at 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), FRANCE, Paris, 25 October 2017 - 28 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413730202114&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Jokubaitis VG; Havrdova E; Horakova D; Izquierdo G; Kalincik T; van der Walt A; Nguyen A-L; Terzi M; Alroughani R; Duquette P; Girard M; Prat A; Boz C; Sola P; Lugaresi A; Lechner-Scott J; Barnett M; Grand'Maison F; Grammond P; Ramo C; Turkoglu R; McCombe P; Hupperts R; Bolanos RF; Pucci E; Trojano M; Granella F; Spitaleri D; Van Pesch V; Soysal A; Oreja-Guevara C; Verheul F; Vucic S; Hodgkinson S; Slee M; Ampapa R; Prevost J; Menoyo JLS; Skibina O; Iuliano G; Solaro C; Olascoaga J; Shaw C; Madsen K; Naidoo K; Hyde R; Butzkueven H, 2017, 'Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, FRANCE, Paris, pp. 130 - 132, presented at 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), FRANCE, Paris, 25 October 2017 - 28 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413730200200&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Jokubaitis V; Ai-Lan N; Kalincik T; van der Walt A; Lechner-Scott J; Barnett M; McCombe P; Vucic S; Hodgkinson S; Slee M; Skibina O; Shaw C; Butzkueven H, 2017, 'Pregnancy incidence, therapy exposure and post-partum relapse risk: a 12-year retrospective multicentre analysis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, AUSTRALIA, MS Res Australia, Sydney, pp. NP4 - NP4, presented at Progress in MS Research Conference, AUSTRALIA, MS Res Australia, Sydney, 11 October 2017 - 13 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000414783200010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Firtko A; Thomas P; Hodgkinson S, 2017, 'Effect of Post-Acute Nurse Led Stroke Clinic (PASC) on readmissions rates for TIA/Stroke', in INTERNATIONAL JOURNAL OF STROKE, SAGE PUBLICATIONS LTD, pp. 10 - 11, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000408220500026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Wilcox P; Robinson CM; Verma ND; Nomura M; Tran GT; Carter N; Boyd R; Hodgkinson SJ; Hall BM, 2017, 'CD8 Expression Increases Suppressive Ability of CD4+CD25+Treg and is a Marker of Antigen-Specificity', in TRANSPLANTATION, LIPPINCOTT WILLIAMS & WILKINS, CANADA, Victoria, pp. S37 - S37, presented at 15th Transplantation Science Symposium (TSS) of the Transplantation-Society, CANADA, Victoria, 24 May 2017 - 26 May 2017, http://dx.doi.org/10.1097/01.tp.0000520351.47820.c8
Verma ND; Robinson CM; Tran GT; Hodgkinson SJ; Hall BM, 2017, 'Human CD4+CD25+CD127loFOXP3+Treg Activation by IL-4 and Alloantigen Induces Activated Treg that do not Express CD45RA and Express the IL-5 Receptor Alpha (CD125)', in TRANSPLANTATION, LIPPINCOTT WILLIAMS & WILKINS, CANADA, Victoria, pp. S7 - S7, presented at 15th Transplantation Science Symposium (TSS) of the Transplantation-Society, CANADA, Victoria, 24 May 2017 - 26 May 2017, http://dx.doi.org/10.1097/01.tp.0000520300.20897.2c
Hall BM; Hall RM; Verma ND; Robinson CM; Wilcox P; Tran GT; Wang C; Sharland A; Hodgkinson SJ, 2017, 'Interleukin 5 (IL-5) Treatment Prevents Chronic Allograft Rejection by Promoting IL-5 Receptor Expressing CD4+CD25+T Regulatory Ts2 Cells', in TRANSPLANTATION, LIPPINCOTT WILLIAMS & WILKINS, CANADA, Victoria, pp. S43 - S43, presented at 15th Transplantation Science Symposium (TSS) of the Transplantation-Society, CANADA, Victoria, 24 May 2017 - 26 May 2017, http://dx.doi.org/10.1097/01.tp.0000520363.08810.76
Verma N; Robinson CM; Tran GT; Hall RM; Wilcox P; Hodgkinson SJ; Hall BM, 2016, 'Activation of Human CD4+CD25+CD127loFOXP3+Treg by IL-4 and alloantigen induces activated Treg that do not express CD45RA and express the IL-5 receptor alpha (CD125)', in TRANSPLANTATION, LIPPINCOTT WILLIAMS & WILKINS, pp. S460 - S460, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000436953201100&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hodgkinson SJ; Hall BM; Hall RM; Robinson CM; Wilcox P; Tran GT; Wang C; Sharland A, 2016, 'Interleukin-5 therapy prevents chronic allograft rejection by induction of antigen specific CD4+CD25+T regulatory cells', in TRANSPLANTATION, LIPPINCOTT WILLIAMS & WILKINS, pp. S65 - S65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000436953200108&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hall BM; Robinson CM; Wilcox P; Verma ND; Tran GT; Carter N; Boyd RA; Hodgkinson SJ, 2016, 'Recently alloactivated CD4+CD8-CD25+Treg express CD8 and are the antigen-specific Treg', in TRANSPLANTATION, LIPPINCOTT WILLIAMS & WILKINS, pp. S120 - S120, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000436953200190&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Jokubaitis VG; Li V; Kalincik T; Izquierdo G; Hodgkinson S; Alroughani R; Lechner-Scott J; Lugaresi A; Duquette P; Girard M; Barnett M; Grand'Maison F; Trojano M; Slee M; Giuliani G; Shaw C; Boz C; Haartsen J; Liew D; Butzkueven H, 2013, 'Does switching to fingolimod from natalizumab result in short-term relapse exacerbation?', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, DENMARK, Copenhagen, pp. 55 - 56, presented at 29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, DENMARK, Copenhagen, 02 October 2013 - 05 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000328751400086&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Cordato DJ; Thomas PR; Darshan G; Sanjeev T; Worthington JM; McDougall AJ; Hodgkinson SJ; Ibrahim HY; Griffith NC; Cappelen-Smith C; Beran RG, 2010, 'Decreasing Presentations of Seizures to Emergency Departments in a Large Australian Population', in NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, CANADA, Toronto, pp. A258 - A258, presented at 62nd Annual Meeting of the American-Academy-of-Neurology, CANADA, Toronto, 10 April 2010 - 17 April 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000275274001259&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Back to profile page
https://orcid.org/0000-0002-9029-6663